EP0644754A4 - Blutstillende Substanz für chirurgische, medizinische und zahnärztliche Verwendung/ Substanz in Pulverform 001 zur Blutstillung während chirurgischer Eingriffe in der Medizin, Zahnmedizin oder bei Blutungen jedweder Ursache. - Google Patents

Blutstillende Substanz für chirurgische, medizinische und zahnärztliche Verwendung/ Substanz in Pulverform 001 zur Blutstillung während chirurgischer Eingriffe in der Medizin, Zahnmedizin oder bei Blutungen jedweder Ursache.

Info

Publication number
EP0644754A4
EP0644754A4 EP92901379A EP92901379A EP0644754A4 EP 0644754 A4 EP0644754 A4 EP 0644754A4 EP 92901379 A EP92901379 A EP 92901379A EP 92901379 A EP92901379 A EP 92901379A EP 0644754 A4 EP0644754 A4 EP 0644754A4
Authority
EP
European Patent Office
Prior art keywords
bleeding
powder
surgery
substance
stop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92901379A
Other languages
English (en)
French (fr)
Other versions
EP0644754A1 (de
Inventor
Leslie Binshyang Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0644754A1 publication Critical patent/EP0644754A1/de
Publication of EP0644754A4 publication Critical patent/EP0644754A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof

Definitions

  • P ⁇ TN ⁇ IK 1971 stated that the concentration of ascorbic acid has been reported as decrea ⁇ ingvith age in the rat eye lens, adrenal, brain, testis, and blood.
  • Purpura (extensive bruising ) and hemorrhages under the tongue are common in elderly people. Tattersal and Seville 1950 reported purpura in 60 out of 009 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and fore- ornv. and on tr.e backs of their hands, noth p-it ientj.
  • THIS invention pertains to the field of disorder of hem ⁇ stasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboe bolic disorders.
  • the blood coagulation mechanism of ascorbic acid which - was administered topically does not fall into either intrinsic or extrinsic pathway cascade, since it works the same for hemosta ⁇ i ⁇ in normal situation as in chronic- hepatitis, colon cancer, and hemophilia patients in whom the coagulation factors 2, 7, 9, 10 in the liver dise and factor 8 or 9 in the hemophilia A or B cannot be produ
  • the present methods available to stop bleeding in surger are cautery, epinephrine injection, pressure and some fiber foam.
  • the cautery can cause tissue necrosis in some cases.
  • the epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly >r* ⁇ ⁇ for diffuse capillary bleeding and any traditionally un ⁇ controllable bleeding tendency patients such as for patient with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency nf the kinds of aforementioned patients.
  • the ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRN ⁇ in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
  • Substance powder 001 represents ascorbic acid powder that i c obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding wnen spraying it topically on the bleeding area for any with the blood, the black tar gel like material is formed, and later becomes solid. The amount of the powder that is needed to react completely with the blood is proportional to the amount of the blood that comes out of the blood vessels. In rats, one capillary, one venous and one femoral artery bleeding were stanched within one second, if sufficien amounts of the powder of ascorbic acid were applied. The arte bleeding needs much more this powder of interest.
  • test tube conditions it requires 0.1568 g of this substance powde to coagulate ( make the blood black and not move in the tube 1 ml of human blood in 6 minutes.
  • This is the same for normal colon cancer a d hemophilia patients; 1 ml of normal blood needs 0.1568 g of ascorbic acid powder, 1 ml of colon cancer blood needs 0.1568 g of ascorbic acid powder, and 1 ml of hemophilia blood needs 0.1568 g of ascorbic acid powder.
  • Suff substance powder 001 is particularly useful to help stop blee in the case of diffuse capillary oozing and mistakenly cut of artery or arteries that cannot be found during massive bleedi bleeding so as to save the patients' lives.
  • the present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, press and some fiber foam.
  • the cautery can cause tissue necrosis in some cases.
  • the epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capillary oozi patients, while ascorbic acid powder does not cause any tissu necrosis and particularly works well for diffuse capillary bl and oozing and any traditionally uncontrollable bleeding tend patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients.
  • the ascorbic acid also facilitate wound healing ( O Surg.
  • the substance powder ool is made by grinding the pure vitamin C tablets into powder. Application of this powder topically to the bleeding area is betber'by spraying the powder topically on the bleeding area.
  • the amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this * vitamin C powder to coagulate 1 ml of human blood. This ⁇ i ⁇ the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this s ⁇ tuation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows: (f) Rats Experiments
  • Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off.
  • Photograph # 1 massive bleeding when the femoral artery is cut off
  • Photogrph # 2 bleeding stops within one second when sufficient powder of interest was poured topically into the bleeding area, in this case of massive active bleeding T did pouring instead of spraying.
  • the amount of the powder needed is proportional to the amount of blood coming out of the vessel. It varies with the rats. Usually 0.1344 g is sufficient to stop bleeding for the femoral artery of the rat which is cut off vithin one second.
  • the black tar gel like material was formed in one second as soon as the powder contacts with the blood .
  • This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
  • tube con il.ion as mentioned previously, ] m ] of human b 1 .nor! requires 0.15C>fl q of powder to form Ma ⁇ -k bloori coa- qulatton by shaking the tube with hand or ⁇ color machine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP92901379A 1990-12-06 1991-12-05 Blutstillende Substanz für chirurgische, medizinische und zahnärztliche Verwendung/ Substanz in Pulverform 001 zur Blutstillung während chirurgischer Eingriffe in der Medizin, Zahnmedizin oder bei Blutungen jedweder Ursache. Withdrawn EP0644754A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62409490A 1990-12-06 1990-12-06
US624094 1990-12-06
PCT/US1991/009201 WO1992010999A1 (en) 1990-12-06 1991-12-05 Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes

Publications (2)

Publication Number Publication Date
EP0644754A1 EP0644754A1 (de) 1995-03-29
EP0644754A4 true EP0644754A4 (de) 1995-12-27

Family

ID=24500629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92901379A Withdrawn EP0644754A4 (de) 1990-12-06 1991-12-05 Blutstillende Substanz für chirurgische, medizinische und zahnärztliche Verwendung/ Substanz in Pulverform 001 zur Blutstillung während chirurgischer Eingriffe in der Medizin, Zahnmedizin oder bei Blutungen jedweder Ursache.

Country Status (5)

Country Link
EP (1) EP0644754A4 (de)
AU (1) AU662505B2 (de)
CA (1) CA2095439C (de)
NO (1) NO930858D0 (de)
WO (1) WO1992010999A1 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336925A1 (fr) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice ou produit similaire
DE2808572A1 (de) * 1977-03-04 1978-09-07 Shiraimatsu Shinyaku Co Haemostatisches mittel
WO1987006465A1 (en) * 1986-04-22 1987-11-05 Olav Johan Braenden Anti-cold kit, anti-cold preparation and use thereof
WO1990012572A1 (en) * 1989-04-17 1990-11-01 Duke University Stable ascorbic acid compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1334933A (en) * 1971-02-19 1973-10-24 Ahrens G W Reaction products of caldium ascorbate and preparation containing them
US4959362A (en) * 1983-12-19 1990-09-25 Takeda Chemical Industries, Inc. Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336925A1 (fr) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice ou produit similaire
DE2808572A1 (de) * 1977-03-04 1978-09-07 Shiraimatsu Shinyaku Co Haemostatisches mittel
WO1987006465A1 (en) * 1986-04-22 1987-11-05 Olav Johan Braenden Anti-cold kit, anti-cold preparation and use thereof
WO1990012572A1 (en) * 1989-04-17 1990-11-01 Duke University Stable ascorbic acid compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTOSZEWSKI Z: "Zastosowanie preparatu Cepevit-K do tamowania krwawien i krwotokow po usunieciu zebow.", POL TYG LEK (POLAND), NOV 20 1972, VOL. 27, NO. 47, PAGE(S) 1861-2, *
DATABASE MEDLINE GURNEY B.F.: "Hemostatic Agents" *
ORAL HYG., vol. 56, no. 7, 1966, pages 78 - 80 *
See also references of WO9210999A1 *

Also Published As

Publication number Publication date
CA2095439A1 (en) 1992-06-07
AU662505B2 (en) 1995-09-07
WO1992010999A1 (en) 1992-07-09
EP0644754A1 (de) 1995-03-29
CA2095439C (en) 1998-12-08
NO930858D0 (no) 1993-03-09
AU9103491A (en) 1992-07-22

Similar Documents

Publication Publication Date Title
US5510391A (en) Method of treating blood vessel disorders of the skin using vitamin K
US6455067B1 (en) Transdermal patch for nonsteroidal antiinflammatory drug(s)
KR101283820B1 (ko) 인 화합물의 흡수를 위한 경구용 조성물
TWI287447B (en) Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
Ramasastry Chronic problem wounds
Rao et al. Extravasation injury to the hand by intravenous phenytoin: report of three cases
WO2024260450A1 (zh) 水溶性番茄浓缩物在制备治疗脑缺血—再灌注损伤的组合物中的应用
Redding Thrombocythemia as a cause of erythermalgia
Sigurdsson et al. Formic acid burn—Local and systemic effects report of a case
EP0532706B1 (de) Verminderung von kardiovaskulären gefässverschlüssen mit ascorbat und hemmstoffen der bindung von lipoprotein (a)
US5114974A (en) Treatment of atherosclerosis with MgNa2 EDTA
AU662505B2 (en) Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes
ES2346649T3 (es) Comprimido recubierto con una pelicula que comprende un extracto de hojas de parra rojas.
Smith et al. Clinical features in patients with the carcinoid syndrome
US6783774B1 (en) Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses
Lau et al. Wound care in the elderly patient
RU2442597C1 (ru) Способ получения экстракта зеленых грецких орехов, используемых в лечебных, пищевых (бад) и косметических целях
Villanueva et al. Dermatologic Manifestations in Renal Disease
Collings et al. Three cases of inoculation of tuberculosis from tattooing
CA3073146C (en) Use of 2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1--yl] acetic acid for making a healing preparation for wounds in patients with diabetes
Krishna Study of Surgincal Complicatons in Diabetic Patients Among The Rural Population
Bacigalupo et al. The effect of heparinization upon vascular healing
Chandler et al. Benign duodeno-colonic fistula
Green Pathology and morbid anatomy
Holman et al. Hypoproteinemia as protection against mercuric chloride injury in dogs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950626

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE

17Q First examination report despatched

Effective date: 19980803

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19980803

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

18D Application deemed to be withdrawn

Effective date: 20050701